vs
Side-by-side financial comparison of FrontView REIT, Inc. (FVR) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
FrontView REIT, Inc. is the larger business by last-quarter revenue ($16.5M vs $9.1M, roughly 1.8× Protalix BioTherapeutics, Inc.). FrontView REIT, Inc. runs the higher net margin — -24.9% vs -60.3%, a 35.5% gap on every dollar of revenue.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
FVR vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.5M | $9.1M |
| Net Profit | $-4.1M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | — | -51.1% |
| Net Margin | -24.9% | -60.3% |
| Revenue YoY | — | -49.9% |
| Net Profit YoY | — | -184.8% |
| EPS (diluted) | $-0.19 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.5M | $9.1M | ||
| Q3 25 | $16.8M | $17.9M | ||
| Q2 25 | $17.6M | $15.7M | ||
| Q1 25 | $16.2M | $10.1M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | $14.5M | $18.0M | ||
| Q2 24 | — | $13.5M | ||
| Q4 23 | — | $10.5M |
| Q4 25 | $-4.1M | $-5.5M | ||
| Q3 25 | $4.0M | $2.4M | ||
| Q2 25 | $-2.9M | $164.0K | ||
| Q1 25 | $-833.0K | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | $-2.4M | $3.2M | ||
| Q2 24 | — | $-2.2M | ||
| Q4 23 | — | $-6.0M |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q4 23 | — | 15.5% |
| Q4 25 | — | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q4 23 | — | -53.5% |
| Q4 25 | -24.9% | -60.3% | ||
| Q3 25 | 23.9% | 13.2% | ||
| Q2 25 | -16.5% | 1.0% | ||
| Q1 25 | -5.1% | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | -16.7% | 18.0% | ||
| Q2 24 | — | -16.4% | ||
| Q4 23 | — | -57.6% |
| Q4 25 | $-0.19 | $-0.06 | ||
| Q3 25 | $0.19 | $0.03 | ||
| Q2 25 | $-0.16 | $0.00 | ||
| Q1 25 | $-0.06 | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | — | $-0.03 | ||
| Q4 23 | — | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.5M | $14.7M |
| Total DebtLower is stronger | $314.3M | — |
| Stockholders' EquityBook value | $391.2M | $48.2M |
| Total Assets | $854.4M | $82.3M |
| Debt / EquityLower = less leverage | 0.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | $14.7M | ||
| Q3 25 | $19.6M | $13.6M | ||
| Q2 25 | $8.4M | $17.9M | ||
| Q1 25 | $3.3M | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q4 23 | — | $23.6M |
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | $391.2M | $48.2M | ||
| Q3 25 | $385.2M | $52.9M | ||
| Q2 25 | $369.9M | $49.9M | ||
| Q1 25 | $324.7M | $45.2M | ||
| Q4 24 | — | $43.2M | ||
| Q3 24 | $1.0K | $32.4M | ||
| Q2 24 | — | $28.6M | ||
| Q4 23 | — | $33.6M |
| Q4 25 | $854.4M | $82.3M | ||
| Q3 25 | $846.8M | $82.3M | ||
| Q2 25 | $856.5M | $78.5M | ||
| Q1 25 | $860.8M | $73.9M | ||
| Q4 24 | — | $73.4M | ||
| Q3 24 | $1.0K | $61.6M | ||
| Q2 24 | — | $91.5M | ||
| Q4 23 | — | $84.4M |
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $42.1M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.1M | $2.0M | ||
| Q3 25 | $8.3M | $-3.7M | ||
| Q2 25 | $9.3M | $-5.2M | ||
| Q1 25 | $8.1M | $-5.1M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $-3.6M | ||
| Q4 23 | — | $3.6M |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | — | $-3.8M | ||
| Q4 23 | — | $3.3M |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 22.4% | ||
| Q2 24 | — | -28.1% | ||
| Q4 23 | — | 31.9% |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.3% | ||
| Q4 23 | — | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | 2.06× | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVR
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
